ArticleScience (New York, N.Y.)2021
Broad betacoronavirus neutralization by a stem helix-specific human antibody.
Open access · hybridAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 312 papers.
0numbers the graph read from it
0cells of the map it votes in
312citing papers in PubMed
22.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
312 citing papers in PubMed, 424 citations in OpenAlex.
- Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines.Cell reports · 2025Trial
- An IgG-like fusion protein comprising an anti-spike S2 antibody and ACE2 exhibits potent and broad neutralization against SARS-CoV-2 and variants of concern.Antibody therapeutics · 2026Article
- Structural basis of diverse antibody recognition of conserved coronavirus spike S2 epitopes that contribute to protective immunity.bioRxiv : the preprint server for biology · 2026Article
- Dissociation kinetics and avidity gate SARS-CoV-2 neutralization by HR2 stem helix antibodies.bioRxiv : the preprint server for biology · 2026Article
- Discovery of human antibody specific to the spike glycoprotein subunit 2 of SARS-CoV-2 and characterization of its broad-spectrum neutralizing activity.Infectious medicine · 2026Article
- An Engineered HR1-Stem Helix-HR2 Trimeric Platform for Developing Broad-Spectrum Coronavirus Vaccines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Identification of Conserved B-Cell Epitope Candidates Associated with Neutralizing Activity of Bovine Coronavirus Spike Protein.Animals : an open access journal from MDPI · 2026Article
- Structural and functional characterization of a conserved cryptic epitope on SARS-CoV-2 spike S2 subunit.PLoS pathogens · 2026Article
- The SARS-CoV-2 S2'-helix compared to stem helix confers higher genetic barrier to antibody resistance.PLoS pathogens · 2026Article
- Directed evolution of a stem-helix-targeting antibody enables MERS-CoV cross-neutralization through enhanced binding affinity.PLoS pathogens · 2026Article
- Addressing the zoonotic threat of merbecoviruses.Nature microbiology · 2026Review
- Targeting SARS-CoV-2 Structural and Accessory Proteins: Emerging Opportunities for Small-Molecule Coronavirus Antivirals.Pharmaceutics · 2026Review
- A designed overlapping variant immunogen pool elicits broad sarbecovirus neutralization.bioRxiv : the preprint server for biology · 2026Article
- Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.Viruses · 2026Review
- Programmable antibody-based chimeric entry receptors for sarbecoviruses.Communications biology · 2026Article
- A cocktail of SARS-CoV-2 S stem helix domain and receptor binding domain human monoclonal antibodies prevents the emergence of viral escape mutants.Microbiology spectrum · 2026Article
- A novel immunoglobulin G- and immunoglobulin cleaving enzyme MG (IceMG), for antibody-mediated rejection.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Update and reuse: Structure-guided nanobody evolution against SARS-CoV-2 escape.PLoS pathogens · 2026Article
- Article
- Monoclonal antibodies from COVID-19 convalescent patients target cryptic epitopes for broad SARS-CoV-2 neutralization.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
252 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors at 12 institutions in 5 countries.
Dora Pinto *Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Maximilian M Sauer *Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0003-0908-0775
Nadine Czudnochowski *Vir Biotechnology, San Francisco, CA 94158, USA.ORCID 0000-0002-3146-4110
Jun Siong Low *Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.ORCID 0000-0002-1775-0778
M Alejandra TortoriciDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0002-2260-2577
Michael P HousleyVir Biotechnology, San Francisco, CA 94158, USA.
Julia NoackVir Biotechnology, San Francisco, CA 94158, USA.ORCID 0000-0002-9113-8181
Alexandra C WallsDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0002-9636-8330
John E BowenDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0003-3590-9727
Barbara GuarinoHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.ORCID 0000-0003-3759-3252
Laura E RosenVir Biotechnology, San Francisco, CA 94158, USA.ORCID 0000-0002-8030-0219
Julia di IulioVir Biotechnology, San Francisco, CA 94158, USA.ORCID 0000-0001-9343-127X
Josipa JerakInstitute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.ORCID 0000-0001-5358-5055
Hannah KaiserVir Biotechnology, San Francisco, CA 94158, USA.ORCID 0000-0002-3991-7401
Saiful IslamVir Biotechnology, San Francisco, CA 94158, USA.
Stefano JaconiHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Nicole SprugasciHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.ORCID 0000-0003-3258-5552
Katja CulapHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.ORCID 0000-0002-0956-0018
Rana AbdelnabiRega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0001-9771-7312
Caroline FooRega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-6380-4917
Lotte CoelmontRega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-7888-4534
Istvan BarthaHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.ORCID 0000-0003-3360-1999
Siro BianchiHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.ORCID 0000-0002-5100-8905
Chiara Silacci-FregniHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Jessica BassiHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.ORCID 0000-0002-4723-6892
Roberta MarziHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.ORCID 0000-0001-6025-6735
Eneida VettiHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Antonino CassottaInstitute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.ORCID 0000-0001-8674-4294
Alessandro CeschiClinical Trial Unit, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.ORCID 0000-0002-4308-0405
Paolo FerrariFaculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.ORCID 0000-0002-9619-3104
Pietro E CippàDepartment of Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Olivier GianniniFaculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.ORCID 0000-0003-2306-0498
Samuele CerutiIntensive Care Unit, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.ORCID 0000-0003-4146-3434
Christian GarzoniClinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.ORCID 0000-0002-0832-2376
Agostino RivaIII Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy.ORCID 0000-0003-3171-3049
Fabio BenigniHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.ORCID 0000-0002-1974-5606
Elisabetta CameroniHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Luca PiccoliHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Matteo S PizzutoHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Megan SmitheyVir Biotechnology, San Francisco, CA 94158, USA.
David HongVir Biotechnology, San Francisco, CA 94158, USA.
Amalio TelentiVir Biotechnology, San Francisco, CA 94158, USA.
Florian A LemppVir Biotechnology, San Francisco, CA 94158, USA.
Johan NeytsRega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium.
Colin Havenar-DaughtonVir Biotechnology, San Francisco, CA 94158, USA.
Antonio LanzavecchiaHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Federica SallustoInstitute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Gyorgy SnellVir Biotechnology, San Francisco, CA 94158, USA.
Herbert W VirginVir Biotechnology, San Francisco, CA 94158, USA.
Martina BeltramelloHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Davide CortiHumabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Vir Biotechnology (Switzerland) · CHVIR Biotechnology (United States) · USUniversity of Washington · USRega Institute for Medical Research · BEUniversità della Svizzera italiana · CHClinica Luganese Moncucco · CHEnte Ospedaliero Cantonale · CHETH Zurich · CHLuigi Sacco Hospital · ITUniversity of Zurich · CHUNSW Sydney · AUWashington University in St. Louis · US
Funding
A Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI KEITH O HODGSON · 2020 to 2026
$43.3MUniversity of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3MUnraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeuticsDP1AI158186 · NIAID · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2020 to 2024
$5.4MAcquisition of a high resolution, high throughput cryo-electron microscopeS10OD023476 · OD · UNIVERSITY OF WASHINGTON · PI KOLLMAN, JUSTIN M · 2017 to 2017
$2.0MNIAID NIH HHS DP1 AI158186NIAID NIH HHS HHSN272201700059CNIAID NIH HHS U01 AI151698NIGMS NIH HHS P30 GM133894NIH HHS S10 OD023476
Abstract
The spillovers of betacoronaviruses in humans and the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants highlight the need for broad coronavirus countermeasures. We describe five monoclonal antibodies (mAbs) cross-reacting with the stem helix of multiple betacoronavirus spike glycoproteins isolated from COVID-19 convalescent individuals. Using structural and functional studies, we show that the mAb with the greatest breadth (S2P6) neutralizes pseudotyped viruses from three different subgenera through the inhibition of membrane fusion, and we delineate the molecular basis for its cross-reactivity. S2P6 reduces viral burden in hamsters challenged with SARS-CoV-2 through viral neutralization and Fc-mediated effector functions. Stem helix antibodies are rare, oftentimes of narrow specificity, and can acquire neutralization breadth through somatic mutations. These data provide a framework for structure-guided design of pan-betacoronavirus vaccines eliciting broad protection.
Indexed as
Virus InternalizationAnimalsAntibodies, MonoclonalAntibodies, NeutralizingBetacoronavirusConvalescenceCricetinaeCross ReactionsHumansImmunoglobulin Fab FragmentsImmunoglobulin Fc FragmentsJurkat CellsLungMembrane FusionNeutralization TestsPeptide MappingAntibodies, MonoclonalAntibodies, NeutralizingImmunoglobulin Fab FragmentsImmunoglobulin Fc FragmentsSpike Glycoprotein, CoronavirusViral Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.